BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 38019516)

  • 21. The prostate: decreasing cost-effectiveness of biopsy with advancing age.
    Gottlieb RH; Mooney C; Mushlin AI; Rubens DJ; Fultz PJ
    Invest Radiol; 1996 Feb; 31(2):84-90. PubMed ID: 8750443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies.
    Roth JA; Gulati R; Gore JL; Cooperberg MR; Etzioni R
    JAMA Oncol; 2016 Jul; 2(7):890-8. PubMed ID: 27010943
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
    Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
    Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
    Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
    Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incorporating Biomarkers into the Primary Prostate Biopsy Setting: A Cost-Effectiveness Analysis.
    Sathianathen NJ; Kuntz KM; Alarid-Escudero F; Lawrentschuk NL; Bolton DM; Murphy DG; Weight CJ; Konety BR
    J Urol; 2018 Dec; 200(6):1215-1220. PubMed ID: 29906434
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Barnett CL; Davenport MS; Montgomery JS; Kunju LP; Denton BT; Piert M
    J Nucl Med; 2019 Dec; 60(12):1705-1712. PubMed ID: 31350321
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.
    Xie J; Namjoshi M; Wu EQ; Parikh K; Diener M; Yu AP; Guo A; Culver KW
    J Manag Care Pharm; 2011 Oct; 17(8):621-43. PubMed ID: 21942303
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Role of Multiparametric Magnetic Resonance Imaging in Active Surveillance for Men with Low-risk Prostate Cancer: A Cost-effectiveness Modeling Study.
    Patel S; Rongen JJ; Fütterer JJ; Boltyenkov A; Rovers MM
    Eur Urol Oncol; 2018 Dec; 1(6):476-483. PubMed ID: 31158091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Choe JH; Abdel-Azim H; Padula WV; Abou-El-Enein M
    JAMA Netw Open; 2022 Dec; 5(12):e2245956. PubMed ID: 36520440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of Pulmonary Rehabilitation Among US Adults With Chronic Obstructive Pulmonary Disease.
    Mosher CL; Nanna MG; Jawitz OK; Raman V; Farrow NE; Aleem S; Casaburi R; MacIntyre NR; Palmer SM; Myers ER
    JAMA Netw Open; 2022 Jun; 5(6):e2218189. PubMed ID: 35731514
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of MRI compared to mammography for breast cancer screening in a high risk population.
    Moore SG; Shenoy PJ; Fanucchi L; Tumeh JW; Flowers CR
    BMC Health Serv Res; 2009 Jan; 9():9. PubMed ID: 19144138
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Racial and Ethnic Disparities in the Use of Prostate Magnetic Resonance Imaging Following an Elevated Prostate-Specific Antigen Test.
    Abashidze N; Stecher C; Rosenkrantz AB; Duszak R; Hughes DR
    JAMA Netw Open; 2021 Nov; 4(11):e2132388. PubMed ID: 34748010
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polygenic risk-tailored screening for prostate cancer: A benefit-harm and cost-effectiveness modelling study.
    Callender T; Emberton M; Morris S; Eeles R; Kote-Jarai Z; Pharoah PDP; Pashayan N
    PLoS Med; 2019 Dec; 16(12):e1002998. PubMed ID: 31860675
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection.
    Ross KS; Carter HB; Pearson JD; Guess HA
    JAMA; 2000 Sep; 284(11):1399-405. PubMed ID: 10989402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk.
    Geuzinge HA; Obdeijn IM; Rutgers EJT; Saadatmand S; Mann RM; Oosterwijk JC; Tollenaar RAEM; de Roy van Zuidewijn DBW; Lobbes MBI; van 't Riet M; Hooning MJ; Ausems MGEM; Loo CE; Wesseling J; Luiten EJT; Zonderland HM; Verhoef C; Heijnsdijk EAM; Tilanus-Linthorst MMA; de Koning HJ;
    JAMA Oncol; 2020 Sep; 6(9):1381-1389. PubMed ID: 32729887
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The cost-effectiveness of prostate cancer screening using the Stockholm3 test.
    Karlsson AA; Hao S; Jauhiainen A; Elfström KM; Egevad L; Nordström T; Heintz E; Clements MS
    PLoS One; 2021; 16(2):e0246674. PubMed ID: 33630863
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis in Biopsy-naive Men with Suspected Prostate Cancer Based on Elevated Prostate-specific Antigen Values: Results from a Randomized Prospective Blinded Controlled Trial.
    Tonttila PP; Lantto J; Pääkkö E; Piippo U; Kauppila S; Lammentausta E; Ohtonen P; Vaarala MH
    Eur Urol; 2016 Mar; 69(3):419-25. PubMed ID: 26033153
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography: The IP1-PROSTAGRAM Study.
    Eldred-Evans D; Burak P; Connor MJ; Day E; Evans M; Fiorentino F; Gammon M; Hosking-Jervis F; Klimowska-Nassar N; McGuire W; Padhani AR; Prevost AT; Price D; Sokhi H; Tam H; Winkler M; Ahmed HU
    JAMA Oncol; 2021 Mar; 7(3):395-402. PubMed ID: 33570542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.